



Revolutionary treatment for Parkinson's enters India

06 December 2018 | News

Nanavati Super Speciality Hospital in collaboration with Parkinson's Centre of Excellence, Kings College, London launch the revolutionary new modality for the treatment of Parkinson's for the first time in India.

Nanavati Super Speciality Hospital in association with **Kings College, London** launched a revolutionary treatment that will change the way Parkinson's has been treated in India. Apomorphine Pen & Pump, the treatment that will radically change the life of a Parkinson's patient will now be available in India. The treatment was launched in Mumbai recently by the **Health Minister of Maharashtra, Dr. Deepak Sawant** and **Paresh Rawal, Actor and Member of Parliament**.

Parkinson's disease is one of the common neurodegenerative diseases affecting the people over the age of 55 years. Parkinson's is characterized by slowness, stiffness and tremors are a special neurodegenerative disorder with very few therapeutic options available. In India, the prevalence of this disease advances between the age of 70-79. It is caused by dopamine deficiency which is a chemical neuro transmitter in the brain mainly in the centers controlling the mobility.

Apomorphine is a highly selective Dopamine receptor stimulator, which promotes the release of dopamine in the brain from the nerve cells that is otherwise absent.

Dr. Rajendra Patankar, COO, Nanavati Super Speciality Hospital said, "Apomorphine is a revolutionary breakthrough to treat the Parkinson's patients. Associating with the prestigious King's College, London has been an honor for us. As a healthcare provider, we would like to commit ourselves to improve the healthcare in India and bring in such great advancements in the field on medicine to India."

The pen and pump treatment is an effective alternative for those who do not want to undergo Deep Brain Stimulation (DBS). According to **Dr. Neeta Shah, Consultant Parkinson's Disease and Movement Disorders Specialist, Nanavati Super Specialty Hospital**, said, "Parkinson's disease in advance stage is a challenge to treat. Patient suffers from progression in symptoms and side effects of increasing dosages of standard medications. We need some novel way to treat this. This treatment will be a boon for such patients."

Speaking about the launch, **Dr. Vinod Metta, Movement Disorders Specialist from London, UK**, who is leading one of the biggest set of patients on Apomorphine in United Kingdom, told that Apomorphine pens work dramatically with giving benefits to patients within couple of minutes and are very similar to usage that of Insulin Pens.